Priority Review for Alnylam's patisiran

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said FDA accepted and granted Priority Review to an NDA for patisiran (ALN-TTR02) to treat hereditary transthyretin (TTR)-mediated amyloidosis. The PDUFA date is Aug. 11.

Last week, EMA accepted an MAA under accelerated assessment for patisiran in the indication...